CellaVision AB
STO:CEVI

Watchlist Manager
CellaVision AB Logo
CellaVision AB
STO:CEVI
Watchlist
Price: 217 SEK 1.17% Market Closed
Market Cap: 5.2B SEK
Have any thoughts about
CellaVision AB?
Write Note

CellaVision AB
Total Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

CellaVision AB
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
CellaVision AB
STO:CEVI
Total Equity
kr767.9m
CAGR 3-Years
15%
CAGR 5-Years
19%
CAGR 10-Years
19%
Elekta AB (publ)
STO:EKTA B
Total Equity
kr10.8B
CAGR 3-Years
10%
CAGR 5-Years
7%
CAGR 10-Years
N/A
S
Surgical Science Sweden AB
STO:SUS
Total Equity
kr4.4B
CAGR 3-Years
9%
CAGR 5-Years
63%
CAGR 10-Years
N/A
Getinge AB
STO:GETI B
Total Equity
kr30.2B
CAGR 3-Years
13%
CAGR 5-Years
9%
CAGR 10-Years
N/A
Arjo AB (publ)
STO:ARJO B
Total Equity
kr7.6B
CAGR 3-Years
10%
CAGR 5-Years
7%
CAGR 10-Years
N/A
S
Stille AB
STO:STIL
Total Equity
kr672.6m
CAGR 3-Years
70%
CAGR 5-Years
47%
CAGR 10-Years
34%
No Stocks Found

CellaVision AB
Glance View

Market Cap
5.2B SEK
Industry
Health Care

CellaVision AB engages in the provision of automated microscopy systems in the field of hematology. The company is headquartered in Lund, Skane and currently employs 200 full-time employees. The company went IPO on 2007-05-28. The firm develops and sells digital solutions for medical microscopy, as well as products enabling blood cell analysis and morphology diagnosis. CellaVision AB’s product portfolio consists of analyzers for automated medical microscopy analysis and software applications designed for remote access, competency testing and education. The analyzers include such brands as CellaVision DM96 and CellaVision DM1200, whereas the software applications are divided into CellaVision Body Fluid Application, CellaVision Remote Review Software and CellaVision Competency Software, among others. The firm operates four subsidiaries, based in Sweden, Canada, the United States and Japan. In June 2014, CellaVision AB acquired technology platform from Clear Lake Medical Foundation.

CEVI Intrinsic Value
265.65 SEK
Undervaluation 18%
Intrinsic Value
Price

See Also

What is CellaVision AB's Total Equity?
Total Equity
767.9m SEK

Based on the financial report for Sep 30, 2024, CellaVision AB's Total Equity amounts to 767.9m SEK.

What is CellaVision AB's Total Equity growth rate?
Total Equity CAGR 10Y
19%

Over the last year, the Total Equity growth was 13%. The average annual Total Equity growth rates for CellaVision AB have been 15% over the past three years , 19% over the past five years , and 19% over the past ten years .

Back to Top